Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851

Delayed Quote. Delayed  - 08/30 09:07:25 am
2.89 EUR   +0.70%
08/26VALNEVA SE : half-yearly earnings release
08/25 VALNEVA : Announces Signing of Marketing & Distribution Agreement fo..
08/25 VALNEVA : Announces Signing of Marketing & Distribution Agreement fo..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CEST

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA SE
08/26VALNEVA SE : half-yearly earnings release
08/25 VALNEVA : Announces Signing of Marketing & Distribution Agreement for Seqirus&rs..
08/25 VALNEVA : Announces Signing of Marketing & Distribution Agreement for Seqirus' F..
07/26 VALNEVA SE : Announces Successful Completion of Phase II for Clostridium Diffici..
07/25 VALNEVA SE : Announces Successful Completion of Phase II for Clostridium Diffici..
07/14 VALNEVA : European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&..
07/13 VALNEVA SE : EIB Grants Valneva a EUR25 Million Loan to Fund R&D Activities
07/12 VALNEVA SE : European Investment Bank Grants Valneva a €25 Million Loan to Fund ..
07/12 VALNEVA : European Investment Bank Grants Valneva a €25 Million Loan to Fund R&D..
07/09 VALNEVA SE : Announces Successful Generation of a Highly-purified Zika Vaccine C..
More news
Sector news : Biotechnology & Medical Research - NEC
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials (€)
Sales 2016 101 M
EBIT 2016 -7,80 M
Net income 2016 -12,5 M
Debt 2016 31,3 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 574,00
EV / Sales 2016 2,44x
EV / Sales 2017 2,06x
Capitalization 214 M
More Financials
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 5,60 €
Spread / Average Target 95%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Franck Grimaud Chief Executive Officer
Thomas Lingelbach President-Management Board
Frédéric Grimaud Chairman-Supervisory Board
Reinhard Kandera Chief Financial Officer
Klaus Schwamborn Vice President-Discovery Research & Innovation
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA SE-24.47%239
INCYTE CORPORATION-25.01%15 290
CELLTRION, INC.--.--%11 038
LONZA GROUP AG14.78%10 080
QUINTILES TRANSNATIONA..12.76%9 173
ALKERMES PLC-43.98%6 740
More Results